According to the company, the move will automate Celerion’s data acquisition system and provide data management and reporting capabilities in a centralized database.
The integration will also establish data collection consistency across clinical sites, which Celerion said will ensure accurate, high-quality information.
“This offering combines the speed and accuracy of an e-source system with the convenience and access of an EDC,” said Michelle Combs, vice president of Data Management and Biometrics.
“EDC’s are commonly used for the management of clinical trial data, but the data cannot be managed until entry has taken place by the site,” she told us.
However, the combination of TrialMaster and ClinQuick enables the company to electronically populate the study database, which Combs said reduces the time, effort, and risk of error associated with manual data entry.
“In a nutshell, this enables Celerion to expand from first-in-human studies to more expanded proof-of-concept multi-site studies very quickly with little additional effort and with seamless access to data,” she added.
Last year, Celerion implemented Verified Clinical Trials’ (VCT) biometric fingerprint technology to address the significant amount of participants dual enrolling at Phase I units, Phil Bach, vice president, Global Clinical Research, Celerion, told us at the time.